ADVFN Logo ADVFN

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

AZN Astrazeneca Plc

11,994.00
112.00 (0.94%)
14 Mar 2025 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Astrazeneca Plc LSE:AZN London Ordinary Share GB0009895292 ORD SHS $0.25
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  112.00 0.94% 11,994.00 11,994.00 12,000.00 12,018.00 11,854.00 11,860.00 2,284,602 16:29:59
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Pharmaceutical Preparations 54.07B 7.04B 4.5370 26.44 184.24B

AstraZeneca PLC ASTRAZENECA ANNOUNCES INVESTMENT IN MODERNA (8445G)

10/08/2016 2:41pm

UK Regulatory


Astrazeneca (LSE:AZN)
Historical Stock Chart


From Mar 2020 to Mar 2025

Click Here for more Astrazeneca Charts.

TIDMAZN

RNS Number : 8445G

AstraZeneca PLC

10 August 2016

This announcement contains inside information

10 August 2016 14:35

ASTRAZENECA ANNOUNCES INVESTMENT IN MODERNA

AstraZeneca today announced that it has increased its equity interest in Moderna Therapeutics (Moderna) with a $140 million investment as part of Moderna's preferred-stock financing.

AstraZeneca previously acquired an equity stake in Moderna following a collaboration agreement, announced in March 2013, to develop messenger RNA medicines for the potential treatment of selected areas of cardiovascular, metabolic and renal diseases as well as oncology. AstraZeneca and Moderna also entered into a further collaboration agreement in January 2016, to discover, co-develop and co-commercialise medicine candidates for the treatment of a range of cancers.

As a result of today's investment, AstraZeneca's ownership of Moderna will be approximately 9% on a fully diluted basis. The additional contribution will be recorded as an equity securities investment.

About Moderna Therapeutics

Moderna is a clinical stage pioneer of messenger RNA Therapeutics(TM), an entirely new in vivo drug technology that produces human proteins, antibodies and entirely novel protein constructs inside patient cells, which are in turn secreted or active intracellularly. This breakthrough platform addresses currently undruggable targets and offers a superior alternative to existing drug modalities for a wide range of diseases and conditions. Moderna is developing and plans to commercialize its innovative mRNA drugs through its own ventures and its strategic relationships with established pharmaceutical and biotech companies. Its current ventures are: Onkaido, focused on oncology, Valera, focused on infectious diseases, Elpidera, focused on rare diseases, and Caperna, focused on personalized cancer vaccines. Cambridge-based Moderna is privately held and currently has strategic agreements with AstraZeneca, Alexion Pharmaceuticals, Merck and Vertex Pharmaceuticals. To learn more, visit www.modernatx.com.

About AstraZeneca

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Respiratory & Autoimmunity, Cardiovascular & Metabolic Diseases, and Oncology. The Company is also active in inflammation, infection and neuroscience through numerous collaborations. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information please visit: www.astrazeneca.com

CONTACTS

 
 Media Enquiries 
 Neil Burrows           UK/Global                     +44 203 749 5637 
 Vanessa Rhodes         UK/Global                     +44 203 749 5736 
 Karen Birmingham       UK/Global                     +44 203 749 5634 
 Rob Skelding           UK/Global                     +44 203 749 5821 
 Jacob Lund             Sweden                        +46 8 553 260 20 
 Michele Meixell        US                            +1 302 885 2677 
 Investor Relations 
 UK 
 Thomas Kudsk Larsen                                  +44 203 749 5712 
                        Finance, Fixed Income, 
 Craig Marks             M&A                          +44 7881 615 764 
 Nick Stone             Respiratory & Autoimmunity    +44 203 749 5716 
 Henry Wheeler          Oncology                      +44 203 749 5797 
 Christer Gruvris       Infection & Neuroscience      +44 203 749 5711 
 US 
                        Cardiovascular & Metabolic 
 Lindsey Trickett        Diseases                     +1 240 543 7970 
 Mitchell Chan           Oncology                     +1 240 477 3771 
 Toll free                                            +1 866 381 7277 
 

Adrian Kemp

Company Secretary

AstraZeneca PLC

-ENDS-

This information is provided by RNS

The company news service from the London Stock Exchange

END

MSCGGUMWRUPQGWU

(END) Dow Jones Newswires

August 10, 2016 09:41 ET (13:41 GMT)

1 Year Astrazeneca Chart

1 Year Astrazeneca Chart

1 Month Astrazeneca Chart

1 Month Astrazeneca Chart